CO6280485A2 - Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina - Google Patents

Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina

Info

Publication number
CO6280485A2
CO6280485A2 CO10035487A CO10035487A CO6280485A2 CO 6280485 A2 CO6280485 A2 CO 6280485A2 CO 10035487 A CO10035487 A CO 10035487A CO 10035487 A CO10035487 A CO 10035487A CO 6280485 A2 CO6280485 A2 CO 6280485A2
Authority
CO
Colombia
Prior art keywords
alkyl
haloalkyl
cycloalkyl
nr9so2r9a
nr9cor9a
Prior art date
Application number
CO10035487A
Other languages
English (en)
Spanish (es)
Inventor
Jun Li
James Li
Michael Galella
Chenkou Wei
Reginald O Cann
Laxma Kolla
Rajendra P Deshpande
Xinhua Qian
Jie Li
Haixia Wang
Lawrence J Kennedy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40523804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6280485(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6280485A2 publication Critical patent/CO6280485A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO10035487A 2007-10-01 2010-03-25 Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina CO6280485A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97650607P 2007-10-01 2007-10-01
US12/206,801 US8119658B2 (en) 2007-10-01 2008-09-09 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Publications (1)

Publication Number Publication Date
CO6280485A2 true CO6280485A2 (es) 2011-05-20

Family

ID=40523804

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10035487A CO6280485A2 (es) 2007-10-01 2010-03-25 Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina

Country Status (20)

Country Link
US (2) US8119658B2 (enExample)
EP (1) EP2205598A1 (enExample)
JP (1) JP5611044B2 (enExample)
KR (1) KR20100085081A (enExample)
CN (1) CN101883772B (enExample)
AR (1) AR068601A1 (enExample)
AU (1) AU2008309101B2 (enExample)
BR (1) BRPI0817656A2 (enExample)
CA (1) CA2701355A1 (enExample)
CL (1) CL2008002916A1 (enExample)
CO (1) CO6280485A2 (enExample)
EA (2) EA201391705A1 (enExample)
IL (1) IL204799A (enExample)
MX (1) MX2010003565A (enExample)
NZ (1) NZ584386A (enExample)
PE (2) PE20121704A1 (enExample)
SG (1) SG190638A1 (enExample)
TW (1) TW200916470A (enExample)
WO (1) WO2009045753A1 (enExample)
ZA (1) ZA201002043B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MX2010002536A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
CN102725290B (zh) 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
EP2519521B1 (en) 2009-12-29 2013-11-20 Eli Lilly and Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PH12013500275A1 (en) 2010-08-10 2017-08-23 Abbvie Inc Novel trpv3 modulators
IN2013MN00581A (enExample) 2010-09-03 2015-06-05 Piramal Entpr Ltd
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CN102180875B (zh) * 2011-03-18 2013-01-16 浙江工业大学 一种三唑并吡啶衍生物的制备方法
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
JP5901025B2 (ja) * 2011-04-19 2016-04-06 第一三共株式会社 テトラヒドロチアゼピン誘導体
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013062966A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
EA202192105A3 (ru) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為ｌｓｄ１抑制劑之環丙胺
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
CR20180109A (es) * 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN114426516B (zh) * 2022-02-16 2022-11-04 安徽有吉医药科技有限公司 一种2-氨基-3-溴吡啶的制备方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558071A (enExample) 1956-06-16
US3597423A (en) 1966-08-31 1971-08-03 Boehringer Mannheim Gmbh 5-nitrofuryl-2-s-triazolo-(4,3-a)-pyridine derivatives
US4358453A (en) 1982-01-08 1982-11-09 Schering Corporation 1,2,4-Triazolo[4,3-a]pyridines
FR2547814B1 (fr) 1983-06-22 1985-10-18 Sanofi Sa Derives de l'acide bicyclo (3.2.1.) octane carboxylique, leur procede de preparation et leur application therapeutique
US4691051A (en) 1985-01-04 1987-09-01 Pennwalt Corporation Adamantyl phenyl β-alanines
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
WO1992018132A1 (en) 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
DE4326758A1 (de) * 1993-08-10 1995-02-16 Basf Ag [1,3,4]Triazolo[1,5-a]pyridine
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
FR2723317B1 (fr) 1994-08-04 1996-10-31 Sanofi Sa Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques
IL125364A0 (en) 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
GB9624611D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds
WO1998043946A1 (en) 1997-03-28 1998-10-08 Zeneca Limited Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
JP2001526178A (ja) 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
EP1475371A1 (en) 1997-12-16 2004-11-10 Warner-Lambert Company LLC 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1999037668A1 (de) 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombininhibitoren
BR0010139A (pt) 1999-04-28 2004-03-02 Reddy Research Foundation Heterociclos bicìclicos substituìdos, processo para seu preparo e seu uso como agentes anti-obesidade e hipocolesterolêmico
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
WO2001060818A1 (en) 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
JP4747396B2 (ja) 2000-05-17 2011-08-17 日立化成工業株式会社 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
CN1496366A (zh) 2001-03-09 2004-05-12 �Ʒ� 作为抗炎剂的三唑并吡啶
JP4225787B2 (ja) 2001-03-27 2009-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬
JP4776810B2 (ja) 2001-05-30 2011-09-21 日本曹達株式会社 α位トリ置換酢酸の製造方法
US20030114460A1 (en) 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CA2474000A1 (en) 2002-01-31 2003-08-07 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
BR0313961A (pt) 2002-08-30 2005-07-19 Pfizer Prod Inc Processos e intermediários para preparar triazolo-piridinas
US20040209858A1 (en) 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
ATE334131T1 (de) 2003-02-14 2006-08-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende verbindungen
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
EP1619948A4 (en) 2003-05-05 2007-02-14 Neurogen Corp SUBSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS
WO2004106294A2 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
IN2012DN03023A (enExample) 2004-01-26 2015-07-31 Merck Sharp & Dohme
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
WO2006018718A2 (en) 2004-08-12 2006-02-23 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
BRPI0514327A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos triazolopiridina
US7605168B2 (en) 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
WO2006030805A1 (ja) 2004-09-16 2006-03-23 Astellas Pharma Inc. トリアゾール誘導体またはその塩
US20080171740A1 (en) 2004-09-24 2008-07-17 Smithkline Beecham Corporation Chemical Compounds
CN101039942A (zh) 2004-09-27 2007-09-19 伊利舍医药品公司 磺酰胺类及其用途
BRPI0515931A (pt) 2004-09-29 2008-08-12 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
WO2006038738A1 (ja) 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
ATE512146T1 (de) 2004-10-13 2011-06-15 Merck Patent Gmbh Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
WO2006040039A1 (de) 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006047631A2 (en) 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Anti-mitotic anti-proliferative compounds
EP1807072B1 (en) 2004-10-29 2009-01-07 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
AU2005311451A1 (en) 2004-12-01 2006-06-08 Merck Serono Sa [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
EP1841723A1 (en) 2004-12-31 2007-10-10 Universität Dortmund Decaline derived compounds as pharmaceutically active agents
US20060148871A1 (en) 2005-01-05 2006-07-06 Rohde Jeffrey J Metabolic stabilization of substituted adamantane
CA2594116A1 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7343245B2 (en) * 2005-06-09 2008-03-11 Eseis, Inc. Method of processing seismic data to extract and portray AVO information
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors

Also Published As

Publication number Publication date
AR068601A1 (es) 2009-11-18
CN101883772B (zh) 2013-08-14
CN101883772A (zh) 2010-11-10
IL204799A (en) 2014-11-30
KR20100085081A (ko) 2010-07-28
US8119658B2 (en) 2012-02-21
CL2008002916A1 (es) 2010-02-12
NZ584386A (en) 2012-03-30
AU2008309101A1 (en) 2009-04-09
EA201391705A1 (ru) 2014-07-30
CA2701355A1 (en) 2009-04-09
PE20121704A1 (es) 2012-12-17
US20110288051A1 (en) 2011-11-24
US8541444B2 (en) 2013-09-24
EA019706B1 (ru) 2014-05-30
BRPI0817656A2 (pt) 2015-03-31
WO2009045753A1 (en) 2009-04-09
IL204799A0 (en) 2010-11-30
ZA201002043B (en) 2011-05-25
EP2205598A1 (en) 2010-07-14
PE20091219A1 (es) 2009-08-14
JP2010540643A (ja) 2010-12-24
SG190638A1 (en) 2013-06-28
TW200916470A (en) 2009-04-16
MX2010003565A (es) 2010-04-21
EA201000563A1 (ru) 2010-10-29
US20090093516A1 (en) 2009-04-09
AU2008309101B2 (en) 2013-12-12
JP5611044B2 (ja) 2014-10-22

Similar Documents

Publication Publication Date Title
CO6280485A2 (es) Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
BRPI0506817A (pt) inibidores seletivos de quinase
MX340060B (es) Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met.
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
ECSP10010473A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
ATE517885T1 (de) Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CO5611167A2 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c
AR059494A1 (es) Derivados biciclicos de bisamida con actividad pesticida
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
NI201000130A (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica.
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
AR067779A1 (es) Profarmacos dipeptoides y su uso
AR085099A1 (es) Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR047382A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.

Legal Events

Date Code Title Description
FG Application granted